Enterolactone in breast cyst fluid

Correlation with EGF and breast cancer risk

Francesco Boccardo, Gian Luigi Lunardi, Anna Rita Petti, Alessandra Rubagotti

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The purpose of our study was to investigate whether enterolactone does accumulate into breast cyst fluid and whether it correlates with breast cancer risk. We included 258 women who had at least one cyst aspiration and known intracystic cation and epidermal growth factor (EGF) concentration values. For 191 of such women serum aliquots were also available. The median value of serum enterolactone was 17 nM/l (range 1-140nM/l). The median intracystic level of enterolactone was much higher (63 nM/l, range 0-872 nM/l) and was significantly higher in type I cysts (p = 0.000). This cyst type contained also significantly higher levels of EGF (p = 0.000). A direct relationship was found between serum and cyst fluid enterolactone levels (p = 0.000) and between cyst enterolactone and EGF levels (p = 0.03), the latter correlation being evident especially in type II cysts. Twelve patients in the cohort of women were found to have developed a breast cancer. After univariate analysis breast cancer risk was associated with cyst type and especially with EGF concentration. No association was evident for enterolactone concentration. However, enterolactone concentration appeared to significantly decrease the risk of patients with high EGF concentrations. Our results show that enterolactone does accumulate in breast cysts, and that it modulates the risk related to the intracystic level of EGF, which is confirmed to be a strong predictor of breast cancer risk.

Original languageEnglish
Pages (from-to)17-23
Number of pages7
JournalBreast Cancer Research and Treatment
Volume79
Issue number1
DOIs
Publication statusPublished - May 2003

Fingerprint

Breast Cyst
Cyst Fluid
Epidermal Growth Factor
Breast Neoplasms
Cysts
Serum
2,3-bis(3'-hydroxybenzyl)butyrolactone
Cations

Keywords

  • Breast cancer risk
  • Breast cyst fluid
  • Enterolactone
  • Epidermal growth factor
  • Type I cysts
  • Type II cysts

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Enterolactone in breast cyst fluid : Correlation with EGF and breast cancer risk. / Boccardo, Francesco; Lunardi, Gian Luigi; Petti, Anna Rita; Rubagotti, Alessandra.

In: Breast Cancer Research and Treatment, Vol. 79, No. 1, 05.2003, p. 17-23.

Research output: Contribution to journalArticle

Boccardo, Francesco ; Lunardi, Gian Luigi ; Petti, Anna Rita ; Rubagotti, Alessandra. / Enterolactone in breast cyst fluid : Correlation with EGF and breast cancer risk. In: Breast Cancer Research and Treatment. 2003 ; Vol. 79, No. 1. pp. 17-23.
@article{9112b7a51bb94da785d1571c8e13c218,
title = "Enterolactone in breast cyst fluid: Correlation with EGF and breast cancer risk",
abstract = "The purpose of our study was to investigate whether enterolactone does accumulate into breast cyst fluid and whether it correlates with breast cancer risk. We included 258 women who had at least one cyst aspiration and known intracystic cation and epidermal growth factor (EGF) concentration values. For 191 of such women serum aliquots were also available. The median value of serum enterolactone was 17 nM/l (range 1-140nM/l). The median intracystic level of enterolactone was much higher (63 nM/l, range 0-872 nM/l) and was significantly higher in type I cysts (p = 0.000). This cyst type contained also significantly higher levels of EGF (p = 0.000). A direct relationship was found between serum and cyst fluid enterolactone levels (p = 0.000) and between cyst enterolactone and EGF levels (p = 0.03), the latter correlation being evident especially in type II cysts. Twelve patients in the cohort of women were found to have developed a breast cancer. After univariate analysis breast cancer risk was associated with cyst type and especially with EGF concentration. No association was evident for enterolactone concentration. However, enterolactone concentration appeared to significantly decrease the risk of patients with high EGF concentrations. Our results show that enterolactone does accumulate in breast cysts, and that it modulates the risk related to the intracystic level of EGF, which is confirmed to be a strong predictor of breast cancer risk.",
keywords = "Breast cancer risk, Breast cyst fluid, Enterolactone, Epidermal growth factor, Type I cysts, Type II cysts",
author = "Francesco Boccardo and Lunardi, {Gian Luigi} and Petti, {Anna Rita} and Alessandra Rubagotti",
year = "2003",
month = "5",
doi = "10.1023/A:1023356209478",
language = "English",
volume = "79",
pages = "17--23",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York LLC",
number = "1",

}

TY - JOUR

T1 - Enterolactone in breast cyst fluid

T2 - Correlation with EGF and breast cancer risk

AU - Boccardo, Francesco

AU - Lunardi, Gian Luigi

AU - Petti, Anna Rita

AU - Rubagotti, Alessandra

PY - 2003/5

Y1 - 2003/5

N2 - The purpose of our study was to investigate whether enterolactone does accumulate into breast cyst fluid and whether it correlates with breast cancer risk. We included 258 women who had at least one cyst aspiration and known intracystic cation and epidermal growth factor (EGF) concentration values. For 191 of such women serum aliquots were also available. The median value of serum enterolactone was 17 nM/l (range 1-140nM/l). The median intracystic level of enterolactone was much higher (63 nM/l, range 0-872 nM/l) and was significantly higher in type I cysts (p = 0.000). This cyst type contained also significantly higher levels of EGF (p = 0.000). A direct relationship was found between serum and cyst fluid enterolactone levels (p = 0.000) and between cyst enterolactone and EGF levels (p = 0.03), the latter correlation being evident especially in type II cysts. Twelve patients in the cohort of women were found to have developed a breast cancer. After univariate analysis breast cancer risk was associated with cyst type and especially with EGF concentration. No association was evident for enterolactone concentration. However, enterolactone concentration appeared to significantly decrease the risk of patients with high EGF concentrations. Our results show that enterolactone does accumulate in breast cysts, and that it modulates the risk related to the intracystic level of EGF, which is confirmed to be a strong predictor of breast cancer risk.

AB - The purpose of our study was to investigate whether enterolactone does accumulate into breast cyst fluid and whether it correlates with breast cancer risk. We included 258 women who had at least one cyst aspiration and known intracystic cation and epidermal growth factor (EGF) concentration values. For 191 of such women serum aliquots were also available. The median value of serum enterolactone was 17 nM/l (range 1-140nM/l). The median intracystic level of enterolactone was much higher (63 nM/l, range 0-872 nM/l) and was significantly higher in type I cysts (p = 0.000). This cyst type contained also significantly higher levels of EGF (p = 0.000). A direct relationship was found between serum and cyst fluid enterolactone levels (p = 0.000) and between cyst enterolactone and EGF levels (p = 0.03), the latter correlation being evident especially in type II cysts. Twelve patients in the cohort of women were found to have developed a breast cancer. After univariate analysis breast cancer risk was associated with cyst type and especially with EGF concentration. No association was evident for enterolactone concentration. However, enterolactone concentration appeared to significantly decrease the risk of patients with high EGF concentrations. Our results show that enterolactone does accumulate in breast cysts, and that it modulates the risk related to the intracystic level of EGF, which is confirmed to be a strong predictor of breast cancer risk.

KW - Breast cancer risk

KW - Breast cyst fluid

KW - Enterolactone

KW - Epidermal growth factor

KW - Type I cysts

KW - Type II cysts

UR - http://www.scopus.com/inward/record.url?scp=0038703516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038703516&partnerID=8YFLogxK

U2 - 10.1023/A:1023356209478

DO - 10.1023/A:1023356209478

M3 - Article

VL - 79

SP - 17

EP - 23

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -